Trials / Completed
CompletedNCT05802810
The Mass Balance Study of [14C]JT001
The Mass Balance Study of [14C]JT001 in Chinese Healthy Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Shanghai Vinnerna Biosciences Co., Ltd. · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study is a single center, single dose, non-randomized, open design clinical study.By quantitative analysis of the biological samples of subjects after oral administration of \[14C\]JT001, the data of human radioactive excretion rate and the main excretion pathway will be obtained. The main metabolites ,metabolic pathways and elimination pathways of JT001 will be identified.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]JT001 | Subjects will receive approximately 300 mg/100 µCi of \[14C\]JT001 orally. |
Timeline
- Start date
- 2023-03-18
- Primary completion
- 2023-09-27
- Completion
- 2023-09-27
- First posted
- 2023-04-07
- Last updated
- 2025-06-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05802810. Inclusion in this directory is not an endorsement.